REG - Ergomed plc - Board Change

ErgomedAnnouncement

18/09/2019 07:05

RNS Number : 6881M
Ergomed plc
18 September 2019
 


 
PRESS RELEASE
 
Board Change
 
 
Guildford, UK - 18 September 2019: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that Dr Jan Petracek has stepped down as Ergomed's Chief Operating Officer and Board Director, as well as CEO of PrimeVigilance, on 17th September 2019.
 
Jan joined Ergomed as part of the acquisition of PharmInvent in November 2016. PrimeVigilance has more than doubled revenues since 2016, including acquisitions, and now employs more than 500 staff. Resuming his career focus on professional, educational and scientific activities, Jan will remain with Ergomed in a consulting capacity to ensure the smooth transition of leadership and to continue his services to PrimeVigilance's clients as a Qualified Person responsible for Pharmacovigilance (QPPV), auditor and strategic advisor.
 
Jonathan West, currently Chief Business Officer of PrimeVigilance, will take on the role of President of PrimeVigilance. With 20 years' experience in pharmacovigilance services, Jonathan first joined Ergomed in 2008 to establish PrimeVigilance as a pharmacovigilance specialist services company. He held the positions of Director of Business Operations and Commercial Director & QPPV, and was appointed Chief Business Officer in August 2018.
 
Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Jan has made a huge contribution to the successful growth of PrimeVigilance and Ergomed's pharmacovigilance offering. The pharmacovigilance business is expected to show revenues increasing 32% to £16.0 million in the first half of 2019 from £12.1 million in the first half of 2018. We look forward to continuing to benefit from Jan's expertise. We are delighted to have Jonathan continuing in his role within Ergomed and taking up the new position as President of PrimeVigilance to drive the further development of the business."
 
Dr Jan Petracek said: "PrimeVigilance has grown very rapidly and it has been a huge privilege to have been part of that journey. I am grateful for the opportunity to continue to make a contribution, and to assist in the smooth transition to support the company's ongoing success."
 
 
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOALFFEIAAIDLIA